Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction
First Claim
1. A compound of formula (XI):
-
wherein R3 is C1 to C6 alkyl optionally substituted with C1-C4 alkoxy;
R4 is SO2NR7R8;
R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; and
R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2;
with the proviso that when R3 is ethyl, R4 is not 4-methylpiperizin-1-ylsulfonyl.
0 Assignments
0 Petitions
Accused Products
Abstract
Compounds of formulae (IA) and (IB) or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group; (CH2)nHet or (CH2)nAr, R2 is C1 to C6 alkyl; R3 is C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy; R4 is SO2NR7R8; R5 and R6 are each independently selected from H and C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic group; R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2; Het is an optionally substituted C-linked 5- or 6-membered heterocyclic group; Ar is optionally substituted phenyl; and n is 0 or 1; are potent and selective cGMP PDE5 inhibitors useful in the treatment of, inter alia, male erectile dysfunction and female sexual dysfunction
-
Citations
2 Claims
-
1. A compound of formula (XI):
-
wherein R3 is C1 to C6 alkyl optionally substituted with C1-C4 alkoxy; R4 is SO2NR7R8;
R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group; and
R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2;
with the proviso that when R3 is ethyl, R4 is not 4-methylpiperizin-1-ylsulfonyl.
-
-
2. A process for the preparation of a compound of formula (IXA) or (IXB):
-
comprising reacting a compound of formula (XA) or (XB) respectively;
with a compound of formula (XI);
wherein R1 is C1 to C3 alkyl substituted with C3 to C6 cycloalkyl, CONR5R6 or a N-linked heterocyclic group selected from pyrazolyl, imidazolyl, triazolyl, pyrrolidinyl, piperidinyl, morpholinyl and 4-R9-piperazinyl;
(CH2)nHet or (CH2)nAr;R2 is C1 to C6alkyl;
R3 is C1 to C6 alkyl optionally substituted with C1-C4 alkoxy;
R4 is SO2NR7R8;
R5 and R6 are each independently selected from H and C1 to C4 aikyl optionally substituted with C1 to C4 alkoxy, or, together with the nitrogen atom to which they are attached, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-R9-piperazinyl group;
R7 and R8, together with the nitrogen atom to which they are attached, form a 4-R10-piperazinyl group;
R9 is C1 to C4 alkyl;
R10 is H or C1 to C4 alkyl optionally substituted with OH, C1 to C4 alkoxy or CONH2;
Het is a C-linked 6-membered heterocydic group containing one or two nitrogen atoms as the only heteroatoms therein, optionally in the form of its mono-N-oxide, or a C-linked 5-membered heterocyclic group containing from one to four heteroatoms selected from nitrogen, oxygen and sulphur, wherein either of said heterocyclic groups is optionally substituted with one or two substituents selected from C1 to C4 alkyl optionally substituted with C1 to C4 alkoxy, C1 to C4 alkoxy, halo and NH2;
Ar is phenyl optionally substituted with one or two substituents selected from C1 to C4 alkyl, C1 to C4 alkoxy, halo, CN, CONH2, NO2, NH2, NHSO2 (C1 to C4 alkyl) and SO2NH2;
and n is 0 or 1.
-
Specification